近日，华东师范大学亚欧商学院于紫竹国际教育园区成功举办2025级企业导师见面会暨聘任仪式，正式 聘请了41位来自多元领域的行业领袖与商业精英担任新一届企业导师。此举标志着学院在深化产教融 合、协同育人的战略道路上迈出了坚实的新步伐。 作为亚欧商学院"双导师制"育人模式的核心环节，企业导师项目迄今已成功举办九届。该项目致力于构 建学生与行业领袖之间的高效沟通平台，将前沿的商业实践与严谨的学术理论深度融合，从而引导学生 建立明晰的职业认知并规划其未来发展路径。截至目前，项目已累计汇聚愈200位企业导师，惠及近800 名学子，成为连接校园与产业的重要桥梁。 在聘任仪式上，亚欧商学院中方院长何佳讯教授发表了深刻致辞。他指出，在人工智能技术正深刻重塑 全球商业逻辑的时代背景下，商科教育必须主动求变、积极革新。他期望通过企业导师的智慧引领，帮 助学生精准把握三大核心学习维度：深刻理解商业的根本逻辑、深度扎根特定行业的专业知识、以及深 入体悟商业活动背后的人文与生命价值。 项目主任吴漪老师亦在发言中强调，企业导师项目是学院连接学术殿堂与商业世界的关键纽带。它不仅 为学生开启了一扇洞察真实商业环境的窗口，也为合作企业源源不断 ...

心玮医疗-B(06609)发布公告，于2026年1月22日，该公司斥资224.3万港元回购4万股。 ...

整体来看，有色金属、创新药、消费电子、非银金融等行业表现亮眼，而传统农牧、资源等领域则面临周期性压力。 随着2025财年业绩预告披露进入高峰期，越来越多的港股上市公司发布最新业绩情况。 数据显示，截至目前，已有315家港股上市公司对外披露2025财年业绩预告，其中53家公司预告了截至2025年12月31日的年度业绩情况。 有色金属"盈利担当" 在贵金属价格持续攀升的背景下，有色金属行业成为港股市场最耀眼的板块。紫金矿业此前发布的业绩预告显示，公司预计2025年实现归属于上市公司股 东的净利润为510亿—520亿元，同比增长约59%—62%；扣非净利润475亿—485亿元，同比增长约50%—53%。 紫金黄金国际预计2025年度实现归属于母公司股东净利润约15亿—16亿美元，与上年同期相比将增加约10.2亿—11.2亿美元，同比增加约212%—233%。 赤峰黄金预计2025年度实现归属于上市公司股东的净利润为30亿—32亿元，与上年同期相比，将增加约12.36亿—14.36亿元，同比增加约70%—81%。 洛阳钼业的业绩预告显示，预计2025年度实现归属净利润为200亿元到208亿元，同比增长47.8%到53 ...

Core Insights - The 2026 JPMorgan Healthcare Conference has highlighted significant trends in the biopharmaceutical industry, particularly in mergers and acquisitions (M&A) among multinational corporations (MNCs) [1] - Major acquisitions include Boston Scientific's $14.5 billion purchase of Penumbra and GSK's $2.2 billion acquisition of RAPT Therapeutics, indicating a strong demand for innovative assets [1][6] - The industry is experiencing a "survival of the fittest" phase, with many biotech firms facing operational challenges and some shutting down due to clinical trial failures [2][8] Mergers and Acquisitions - Boston Scientific has announced two major acquisitions: Valencia Technologies Corporation and Penumbra, with the latter being its largest acquisition in nearly 20 years [1][4] - GSK's acquisition of RAPT Therapeutics aims to leverage its global R&D capabilities to enhance the value of RAPT's pipeline [1][6] - The trend of M&A is driven by MNCs facing a "patent cliff," with an estimated $400 billion in revenue at risk over the next decade [4] Industry Dynamics - The demand for high-quality innovative assets is increasing, leading to a surge in business development (BD) and M&A activities in the biopharmaceutical sector [2][4] - The competitive landscape is shifting from product-based competition to pipeline and product integration capabilities among large pharmaceutical companies [7] - Biotech firms are increasingly viewed as valuable partners for MNCs, providing pathways for pipeline realization and cash flow enhancement [2][10] Challenges for Biotech - Nido Biosciences has ceased operations due to clinical trial failures, highlighting the risks faced by biotech companies in the current environment [2][8] - Financial instability and clinical setbacks are common reasons for biotech firms shutting down, with many struggling to secure funding [8][9] - The industry is witnessing a trend where companies must optimize their pipelines and manage resources effectively to survive [9][10] Future Outlook - The biopharmaceutical sector is expected to see continued M&A activity, particularly focusing on late-stage, lower-risk assets as uncertainties in key policies diminish [4] - Chinese biotech firms are increasingly engaging in BD collaborations with MNCs, driven by cost control and R&D efficiency advantages [10][12] - The industry is at a pivotal point, transitioning from quantity-driven growth to a focus on quality and value creation in the global health landscape [12]

"资产配置建议需要足够专业、有深度，同时服务也需便捷。"一位资深客户经理道出了90后高净值人士的私人银行的新期待；而一位60后的实 业家更看重长期关系："我和我的银行客户经理合作超过十年了，他了解我的企业起伏和家庭情况，这种信任和稳定感无可替代。" 两种声音，映射出中国财富管理市场的演变。近日，中国银行（601988）与21世纪经济报道联合发布《2026中国高净值人群财富管理白皮书》 （下称"白皮书"）。白皮书课题组通过近千份有效问卷和40余场深度访谈，揭示了一个超越数字增长的财富新世界——在百年变局加速演进、 全球经济格局深度重构的今天，财富的内涵已不再局限于保值增值，更延伸至代际传承、企业战略乃至人生价值的整体规划。 高净值财富生态的十二个切面 白皮书以宏观图景、人群画像、配置行为、服务需求四大章节为脉络，呈现了高净值人群在结构分层、风险偏好与服务需求上的多元特征，也 给出了中国银行基于此的系统性解决方案。财富的脉动从未如此复杂而生动，让我们一同深入这份白皮书，洞察高净值人群的真实诉求，探寻 中国银行如何以专业回应时代之变。 白皮书开篇凝练的十二项核心发现，清晰展示出了当前高净值人群在客群结构、风险偏好、 ...

中新网武汉1月22日电 湖北省"51020"先进制造业集群产业生态之医工交叉产业对接活动22日在武汉举 行，湖北省医工交叉融合创新产业联盟正式揭牌成立，31项医工交叉融合创新项目及产业化项目达成合 作，意向投资总额约12亿元，涉及医工交叉产业全链条合作，涵盖产学研医融全生态协同。 湖北省医工交叉融合创新产业联盟，是在湖北省经信厅、湖北省卫健委、湖北省药监局等部门指导下组 建的省级医工融合创新转化平台。该联盟汇聚医疗机构、高校院所、投融资机构、医药龙头及专业服务 机构等多家核心单位，构建起"临床需求—技术研发—中试熟化—资本赋能—产业落地"的全链条创新生 态体系。 现场，湖北省2025年医工交叉揭榜挂帅十大创新项目正式发布。湖北省经信厅将对揭榜项目给予最高 500万元资金扶持，推动创新链、产业链、资金链深度融合，加速以生物医药为核心的大健康产业高质 量发展。(完) （文章来源：中国新闻网） 湖北省医工交叉融合创新产业联盟理事长马丁表示，联盟将动员平台机构和医药企业力量，聚焦科创成 果转化早介入、早对接、早融合，在概念验证、中试熟化、临床研究、法规认证、产业化等各环节进行 孵化，培育更多医疗创新型科技企业，不断壮 ...

Market Performance - On January 22, the A-share market experienced a morning surge followed by a pullback, with the three major indices closing in the green, and the ChiNext Index rising nearly 1% [1][6] - The ChiNext 50 ETF (159949) increased by 1.04%, closing at 1.558 yuan, with a turnover rate of 5.20% and a transaction volume of 1.299 billion yuan, ranking first among similar ETFs [1][6] Liquidity and Trading Data - As of January 22, the ChiNext 50 ETF (159949) recorded a cumulative transaction amount of 38.006 billion yuan over the last 20 trading days, with an average daily transaction amount of 1.900 billion yuan; since the beginning of the year, the cumulative transaction amount over 14 trading days was 27.332 billion yuan, with an average daily transaction amount of 1.952 billion yuan [2][7] - The circulating scale of the ChiNext 50 ETF was 24.900 billion yuan as of January 21, 2026 [2][7] Fund Holdings and Performance - The latest quarterly report indicates that the top ten holdings of the ChiNext 50 ETF (159949) showed mixed performance, including stocks like CATL, Zhongji Xuchuang, and Mindray Medical [3][8] - The fund manager noted that the fourth quarter saw a return to structural market trends, with significant divergence in the ChiNext, particularly in sectors like AI and new energy [10] Investment Outlook - The ChiNext 50 ETF is viewed as a convenient tool for long-term investors interested in China's technology growth sector, with a three-year return of 35.16%, outperforming its benchmark and ranking 526th among 1,633 similar products [5][11] - Recommendations for investors include adopting a dollar-cost averaging strategy or phased investment to smooth out short-term volatility while closely monitoring the performance of constituent stocks and relevant policy developments [5][11]

金陵之冬，创意满城。 紫金山科技城开启"6G迎新派对"，机甲麒麟在繁华商圈"赛博"起舞，牛首山2026架无人机绘出马年元 素……辞旧迎新之际，南京举办128场跨年活动，刷新地铁单日运力纪录，带动元旦旅游消费增长显 著。 被科技点亮的夜空，不仅映照城市温度、治理精度，更展现烟火寻常、活力日常。"创新敢为才能破圈 出彩。"一位网民在"南京发布"留言。 立足产业强市之要，南京做好"转强增育"四篇文章，构筑新质生产力主导的产业高地。 ——"转"型攀峰，传统产业固本开新。入选国家首批领航级智能工厂的南京钢铁集团，上万个传感器如 同"智能神经元"遍布产线。一笔耐磨钢订单刚录入系统，"元冶·钢铁大模型"30秒内即算出最佳生产方 案。"从'经验炼钢'钢花飞溅到'智慧炼钢'数据奔流，铁水罐周转率提升5%，每吨铁水降本200元，仅此 一项每年就节省上亿元。"南钢副总裁朱平说。 面向"十五五"，南京将实施传统产业攀峰计划，推动石化、钢铁等产业向价值链中高端迈进，力争 到"十五五"末，化工新材料占石化产业40%，优特钢占钢铁制造超80%。 ——登高做"强"，新兴产业集群跃升。20世纪60年代，东南大学的查礼冠教授团队，仅凭两张机器人 ...

Core Viewpoint - The company, 宜明昂科-B, has seen a stock increase of over 5% following the announcement of successful patient recruitment for a Phase III clinical trial of IMM01 for chronic myelomonocytic leukemia (CMML) treatment, indicating positive momentum in its clinical development and potential future partnerships [1] Group 1: Clinical Development - The company announced the successful recruitment of 104 patients for the Phase III clinical trial of IMM01, aimed at treating CMML, with expectations to complete recruitment of 132 patients by the end of March 2026 [1] - The company plans to submit a pre-BLA application by the end of 2026 and is advancing its research in atherosclerosis to the concept validation stage [1] Group 2: Business Operations - As of the announcement date, the board confirmed that the company's business operations and clinical development remain normal, with no significant adverse changes in the financial status [1] Group 3: Industry Engagement - The company participated in the 44th J.P. Morgan Healthcare Conference, where its founder and CEO, Dr. Tian Wenzhi, presented the company's development status and key project progress [1] - During the conference, the executive team engaged with over ten multinational pharmaceutical and biotechnology companies, establishing deep communication with several potential partners, which is expected to lead to substantial progress in 2026 [1]

消息面上，1月21日晚，宜明昂科发布公告称，公司于2025年12月31日成功完成IMM01(替达派西普)用 于慢性粒-单核细胞白血病(CMML)一线治疗的III期临床试验的104例患者招募，预期将于2026年3月底 前完成中期分析所需的132 例患者招募。此外，公司计划于2026年底递交preBLA申请，其在动脉粥样 硬化领域的Ib/II期研究也将推进至概念验证阶段。截至公告日期，董事会确认集团的业务营运及临床开 发维持正常，且集团的业务营运及财务状况并无重大不利变动。 值得一提的是，据宜明昂科公众号披露，近日，宜明昂科团队一行三人出席了第44届摩根大通医疗健康 年会，公司创始人、董事长、CEO兼CSO田文志博士在Biotech Showcase™ 全面介绍了公司发展状况及 重要项目进展。田文志博士携公司高管团队在会议期间密集约见了十余家跨国药企及生物技术公司，并 在会后已与多家潜在合作伙伴建立深度沟通，反馈积极，2026年有望达成实质性进展，为公司管线全球 化注入新动能。 智通财经APP获悉，宜明昂科-B(01541)涨超5%，截至发稿，涨5.11%，报4.94港元，成交额834.81万港 元。 ...